Very recently, Pena and colleagues carried out an untargeted analysis of urine and plasma metabolome by GC-MS and reported the possible usefulness of a set of metabolites to predict the development of DN on top of the traditional renal risk markers, namely, baseline urinary albumin excretion and baseline estimated glomerular filtration rate [91]. This evidence concerns the gene ALB and liver dysplastic nodule.